These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 26837312

  • 21. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
    Pagani IS, Dang P, Saunders VA, Grose R, Shanmuganathan N, Kok CH, Carne L, Rwodzi Z, Watts S, McLean J, Braley J, Altamura H, Yeung DT, Branford S, Yong ASM, White DL, Hughes TP, Ross DM.
    Leukemia; 2020 Apr; 34(4):1052-1061. PubMed ID: 31768016
    [Abstract] [Full Text] [Related]

  • 22. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
    Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP.
    Blood; 2013 May 09; 121(19):3818-24. PubMed ID: 23515925
    [Abstract] [Full Text] [Related]

  • 23. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.
    Int J Mol Sci; 2019 May 06; 20(9):. PubMed ID: 31064152
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
    Press RD, Kamel-Reid S, Ang D.
    J Mol Diagn; 2013 Sep 06; 15(5):565-76. PubMed ID: 23810242
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
    Goldman J.
    Curr Opin Hematol; 2005 Jan 06; 12(1):33-9. PubMed ID: 15604889
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
    Br J Haematol; 2002 Sep 06; 118(3):771-7. PubMed ID: 12181044
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of Xpert® BCR-ABL Ultra for the confirmation of BCR-ABL1 international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia.
    Dominy KM, Simon IM, Sorouri-Khorashad J.
    Int J Lab Hematol; 2021 Feb 06; 43(1):e31-e34. PubMed ID: 32990400
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
    Beránek M, Voglová J, Sýkorová A, Belada D, Bláha M.
    Cas Lek Cesk; 2006 Feb 06; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
    Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP.
    Leukemia; 2010 Oct 06; 24(10):1719-24. PubMed ID: 20811403
    [Abstract] [Full Text] [Related]

  • 40. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
    Schäfer V, White HE, Gerrard G, Möbius S, Saussele S, Franke GN, Mahon FX, Talmaci R, Colomer D, Soverini S, Machova Polakova K, Cross NCP, Hochhaus A, Ernst T.
    J Cancer Res Clin Oncol; 2021 Oct 06; 147(10):3081-3089. PubMed ID: 33677711
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.